Sentences with phrase «in central nervous system disorders»

Clinical proton MR spectroscopy in central nervous system disorders.

Not exact matches

The company runs clinical studies on behalf of its multinational pharma clients in oncology, respiratory / infectious disease and central nervous system disorders.

The disease is characterized by the accumulation of very long chain fatty acids (VLCFA) leading to a neurodegenerative disorder that is chronically debilitating and life - threatening, where the most affected tissues are the myelin in the central nervous system (CNS) and the adrenal cortex.

Alkermes is a commercial - stage company that focuses on drugs for central nervous system disorders, and could have some major catalysts in 2018.

Palm Oil - Derived Natural Vitamin E a-Tocotrienol in Brain Health and Disease: Scientific literature evaluating the therapeutic potential of tocotrienols (type of vitamin E found in abundance in palm fruit oil) for neurodegenerative disorders of the central nervous system, cancer treatment, and hypercholesterolemia.

«This process may therefore play a key role in neural development and central nervous system function in adults, as well as in chronic brain disorders and various acute brain injuries.»

In the past researchers have observed an association between poor mitochondrial function and Parkinson's disease, a neurodegenerative disorder of the central nervous system that impairs speech and motor functions and affects five million people worldwide.

«Our research should stimulate renewed clinical interest in developing glucocorticoid therapies to treat blast - induced traumatic brain injury (bTBI) and other disorders of the central nervous system,» Morrison says.

The study of almost 8,000 families, published today (21 March) in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

Neurofibromatosis is one of at least 60 genetic diseases called neurocutaneous disorders that involve the skin, central nervous system, and / or peripheral nervous system, according to a comprehensive review article in the journal Current Neurology and Neuroscience Reports by neurologists at Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine.

A newly identified genetic disorder associated with degeneration of the central and peripheral nervous systems in humans, along with the genetic cause, has been discovered by researchers.

A newly identified genetic disorder associated with degeneration of the central and peripheral nervous systems in humans, along with the genetic cause, is reported in the April 24, 2014 issue of Cell.

«And many studies of the brain and central nervous system, using imaging, EEG and other objective measures of brain structure and function, add to the existing evidence that central nervous system dysfunction is a critical element in the disorder.

Epilepsies are amongst the most common disorders of the Central Nervous System, affecting up to 50 million patients in worldwide.

Ritalin, the brand name for methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder, is a growing problem among college students who use it without a prescription as a so - called «study enhancer.»

Multiple sclerosis (MS) is among the most common neurological diseases in young adults, affecting 350 000 individuals in the United States and 2 million worldwide.1 Prevailing thought is that MS is an autoimmune disorder whereby an unknown agent or agents triggers a T cell — mediated inflammatory attack, causing demyelination of central nervous system tissue.2

«We are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness,» said Bioquark CEO Ira Pastor.

Most recently, Dr. Gringeri was the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a Netherlands - based company engaged in human gene therapies for orphan diseases related to metabolic disorders, liver diseases, blood diseases, and disorders of the central and peripheral nervous systems.

In the fall of 2012, their group demonstrated that misfolded versions of α - synuclein, the protein implicated in Parkinson's disease, can be transmitted from cell to cell in mouse models, adding weight to a hypothesis that a common mechanism of neurodegenerative disorders could involve the passage of misfolded proteins through the central nervous systeIn the fall of 2012, their group demonstrated that misfolded versions of α - synuclein, the protein implicated in Parkinson's disease, can be transmitted from cell to cell in mouse models, adding weight to a hypothesis that a common mechanism of neurodegenerative disorders could involve the passage of misfolded proteins through the central nervous systein Parkinson's disease, can be transmitted from cell to cell in mouse models, adding weight to a hypothesis that a common mechanism of neurodegenerative disorders could involve the passage of misfolded proteins through the central nervous systein mouse models, adding weight to a hypothesis that a common mechanism of neurodegenerative disorders could involve the passage of misfolded proteins through the central nervous system.

The study of almost 8,000 families, published in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Simply put, both disorders prevent normal development of the central nervous system, resulting in premature death in children, presenting an urgent need for effective therapeutic intervention.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria

Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.

Both MPS IIIA and GM1 are classified as neuropathic (i.e. affecting the central nervous system) Lysosomal Storage Disorders, a group of approximately 50 rare inherited metabolic disorders that result from defects in lysosomal function.

The endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderIn genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.

Chronic hiccuping is commonly caused by digestive tract problems and, in rare cases, by central nervous system disorders, a Chilean study found.

Deficiency of folate and vitamin B12 is known to cause impaired methylation in the central nervous system, which may lead to neurological disease and other psychiatric disorders.

The changes in the brain seen in people who have seizure disorders are very similar in nature to that of chronic pain and thought to involve increased excitability of neurons, both in the central and peripheral nervous system.

Similarly, altered zinc levels in plasma, enzymes and neurons have been demonstrated in a number of disorders of the central nervous system (Ebadi et al. 1995).

Dr. Sessions has also published articles on certain bacterial infections and central nervous system disorders in dogs.

Dogs who recover from canine distemper may have seizures or other central nervous system disorders that may not show up until many years later - sometimes in their old age.

Not an approved drug for cats Young, growing animals due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Breeding, pregnant or nursing animals Pets who have a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones Directions:

Pregnant or nursing animals Do not use in patients with head trauma, central nervous system disorders, pets with liver disease, respiratory compromise or heart failure Use with caution in geriatric or debilitated pets, those with severe kidney disease, Addison's disease or hypothyroidism If your pet has had an allergic reaction to buprenorphine or other similar drugs Directions:

Young, growing animals due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Should not be used at high doses in cats (may cause blindness) Breeding, pregnant or nursing animals Pets who have a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones and / or sulfonamides Directions:

Use with caution in animals with known or suspected Central Nervous System (CNS) disorders.

Young, growing dogs due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Breeding, pregnant or nursing animals Use with caution in cats at high doses Use with caution in pets with a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones Directions:

Some clinical studies have also established the clinical usefulness of probiotic bacteria in the management of certain disorders of the central nervous system.

Since neonicotinoid pesticides work by impacting insect's central nervous systems, researchers have long raised concerns about the role they could play in Colony Collapse Disorder.

Other side effects include allergic reactions, central nervous system disorders, anxiety, abnormal heart rhythm, photosensitivity (sensitivity to the sun), blood glucose «disturbances,» hepatotoxicity (liver damage), changes in sensation and nerve damage.

It is a genetic, inherited, familial disorder that ultimately results in biochemical imbalances within one's central nervous system.

Parkinson's disease is a degenerative disorder of the central nervous system named for James Parkinson (1755 - 1824), the physician who first described it in 1817.